Ethris
PrivateLast Round
Debt
Sep 10, 2026
Est. Valuation
$154.58M
Total Funding Raised
$96.64M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ethris is a biotechnology company that develops messenger RNA (mRNA) based therapeutics and vaccines, with a focus on respiratory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ethris Comparables
Compare Ethris with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| eTheRNA | 87% | |
| Pantherna Therapeutics | 86% | |
| Genevant Sciences | 85% |
Ethris Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Sep 10, 2026 | ||||
| Grant | May 6, 2025 | ||||
| Grant | Feb 11, 2025 | ||||
| Convertible Debt | Jun 18, 2024 | ||||
| VC Round | Jun 18, 2024 | ||||
Grant | Feb 25, 2024 |
Key People
Founding team and executive leadership
Ethris Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CEPI | Grant |
| European Investment Bank Group | Debt |
| Bill & Melinda Gates Foundation | VC Round |
| European Health and Digital Executive Agency | Grant |
| Central Innovation Program for SMEs | Grant |
| Laureus Capital | Series B |
| EU4Health Programme | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 10, 2026
$35M round led by European Investment Bank Group
- Aug 20, 2026
Monthly visitors increased 129% MoM.
Recent news
Latest coverage and updates
- is_developingSep 10, 2026
Ethris develops ETH53 as a respiratory mRNA program targeting mucosal influenza vaccines and pandemic preparedness.
- is_developingSep 10, 2026
Ethris is developing ETH52 and ETH53, respiratory mRNA programs targeting mucosal influenza vaccines and pandemic preparedness.
- receives_financingSep 10, 2026
Ethris receives $34.8M financing from the European Investment Bank under HERA Invest on Sep 10th '26 in Germany to advance clinical development of its respiratory mRNA portfolio.
Ethris Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ethris's valuation, stock price, and market status.
Is Ethris a public or private company?
Ethris is a private company.
What is the current stock price of Ethris?
Ethris is a private company, so its shares have no public market price. Caplight tracks Ethris's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ethris worth (valuation)?
Ethris's valuation is estimated at $154.6M based on funding round data.
Can I buy Ethris stock?
Ethris shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ethris's last funding round?
Ethris's most recent funding round was Debt on September 10, 2026.
Who are the main investors in Ethris?
Key investors in Ethris include European Investment Bank Group, Bill & Melinda Gates Foundation, Laureus Capital.
Will Ethris IPO soon?
No public IPO plans have been announced for Ethris.
How can I track Ethris secondary market activity?
Caplight tracks bids, offers, and trades in Ethris's shares on secondary markets.